Integrating Chinese herbal medicine in advanced lung cancer: a multicenter real-world study using target trial emulation

The clinical outcomes of integrating Chinese herbal medicine in stage IV non-small cell lung cancer treatment: a multicenter real-world study using target trial emulation and system biology approach

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN78546774

Enrollment

8000

Registered

2025-06-09

Start date

2011-01-01

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage IV non-small cell lung cancer. Cancer

Interventions

Chinese herbal medicine, modified according to illness and physicians' clinical experience (at least 28 days of oral Chinese herbal medicine treatment, twice to three times a day). The follow-up durat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients newly diagnosed with stage IV NSCLC 2. Aged 18 to 80 years

Exclusion criteria

Exclusion criteria: 1. Patients aged <18 or =80 years 2. Errors in diagnosis or death date 3. Missing TNM staging records 4. Non-stage IV NSCLC, or cancer types other than squamous cell (SqCC) and adenocarcinoma (AC)

Design outcomes

Primary

Measure	Time frame
Overall survival (OS), retrieved from the clinical database built up by the Chang Gung Medical Foundation, measured at the end of the study (31/12/2021) or 10 years after diagnosis	—

Secondary

Measure	Time frame
Cancer-specific survival (CSS), retrieved from the clinical database built up by the Chang Gung Medical Foundation, measured at the end of the study (31/12/2021) or 10 years after diagnosis	—

Countries

Taiwan

Contacts

Public ContactHsing-Yu Chen

8705016@cgmh.org.tw+886 (0)975366119

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026